Agreement Termination By Counterparty, Contractual Time Threshold

No definition available.

Name:	nbix_AgreementTerminationByCounterpartyContractualTimeThreshold
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination By Counterparty, Minimal Contractual Time

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationByCounterpartyMinimalContractualTime
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination, Contractual Time Threshold

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationContractualTimeThreshold
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination, Due To Material Breach

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationDueToMaterialBreach
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Agreement Termination, Minimal Contractual Time

+ References

No definition available.

+ Details

Name:	nbix_AgreementTerminationMinimalContractualTime
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Board Of Directors Maximum Duration Term

+ References

No definition available.

+ Details

Name:	nbix_BoardOfDirectorsMaximumDurationTerm
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments made for milestones under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_MilestonePayment
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number Of Gene Therapy Programs

+ References

No definition available.

+ Details

Name:	nbix_NumberOfGeneTherapyPrograms
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Non-clinical Stage Compound

+ References

No definition available.

+ Details

Name:	nbix_NumberOfNonClinicalStageCompound
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Preclinical Candidates

+ References

No definition available.

+ Details

Name:	nbix_NumberOfPreclinicalCandidates
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Undisclosed Programs

+ References

No definition available.

+ Details

Name:	nbix_NumberOfUndisclosedPrograms
Namespace Prefix:	nbix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	nbix_PatentTerm
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential later stage milestone payments and royalties.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePaymentReceipts
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of potential milestone payments to be paid under a license agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePayments
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of shares sold by the collaboration partner per stock transaction.

+ References

No definition available.

+ Details

Name:	nbix_SaleOfStockNumberOfSharesSoldInTransaction
Namespace Prefix:	nbix_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payments made under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_UpfrontPaymentsMade
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Voting Restriction Period

+ References

No definition available.

+ Details

Name:	nbix_VotingRestrictionPeriod
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A

+ Details

Name:	us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.

+ References

+ Details

Name:	us-gaap_EquitySecuritiesFvNiCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A

+ Details

Name:	us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479536/321-10-50-4

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2

+ Details

Name:	us-gaap_InventoryValuationReserves
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_A2019VoyagerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_A2023VoyagerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbix_AbbVieIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) geneTherapyProgram $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 non-clinicalStageCompound	Dec. 31, 2019 USD ($) preclinicalCandidate undisclosedProgram $ / shares shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development	$ 143.9	$ 0.0	$ 105.3
Unrealized gain (loss) included in earnings	28.4	30.8	20.9
Equity securities	161.9	102.1
Inventory reserves	5.2	0.0
Revenues	$ 1,887.1	1,488.7	1,133.5
Collaborative Arrangement \| Common Stock [Member] \| Voyager
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership (as a percent)	19.90%
Collaborative Arrangement \| Heptares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development			$ 100.0
Research and development		30.0
Potential milestone payments	$ 2,600.0
Agreement termination, minimal contractual time (in days)			180 days
Agreement termination, contractual time threshold (in days)			90 days
Agreement termination by counterparty, contractual time threshold (in days)			365 days
Agreement termination by counterparty, minimal contractual time (in days)			120 days
Collaborative Arrangement \| Takeda
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		5.0
Potential milestone payments	1,900.0
Agreement termination, minimal contractual time (in days)				6 months
Agreement termination, contractual time threshold (in days)				12 months
Number of non-clinical stage compounds \| non-clinicalStageCompound				4
Collaborative Arrangement \| Idorsia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments	1,700.0
Agreement termination, minimal contractual time (in days)				90 days
Agreement termination, due to material breach (in days)				90 days
Collaborative Arrangement \| Xenon
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 7.3	$ 5.4
Potential milestone payments	1,700.0
Agreement termination, contractual time threshold (in days)					90 days
Number of preclinical candidates \| preclinicalCandidate					3
Share price (in USD per share) \| $ / shares		$ 31.855	$ 19.9755		$ 14.196
Equity securities purchase date fair value amount			$ 4.6		$ 14.1
Milestone payment		$ 15.0	$ 10.0
Equity securities cost		$ 7.7
Collaborative Arrangement \| Xenon \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares		0.3	0.3		1.4
Collaborative Arrangement \| Voyager
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unrealized gain (loss) included in earnings	15.5	$ 14.5	$ (8.7)
Equity securities	72.4
Collaborative Arrangement \| 2019 Voyager Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payments	$ 1,300.0
Agreement termination, minimal contractual time (in days)					180 days
Agreement termination, contractual time threshold (in days)					1 year
Share price (in USD per share) \| $ / shares					$ 11.9625
Equity securities purchase date fair value amount					$ 54.7
Number of undisclosed programs \| undisclosedProgram					2
Voting restriction period (in years)	3 years
Collaborative Arrangement \| 2019 Voyager Agreement \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares					4.2
Collaborative Arrangement \| 2023 Voyager Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development	$ 143.9
Potential milestone payments	$ 6,100.0
Agreement termination, minimal contractual time (in days)	180 days
Agreement termination, contractual time threshold (in days)	1 year
Share price (in USD per share) \| $ / shares	$ 8.88
Equity securities cost	$ 31.3
Voting restriction period (in years)	3 years
Number of gene therapy programs \| geneTherapyProgram	3
Upfront payments made	$ 175.0
Board of directors maximum duration term (in years)	10 years
Collaborative Arrangement \| 2023 Voyager Agreement \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in shares) \| shares	4.4
Collaborative Arrangement \| BIAL – Portela & Ca, S.A.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Inventory reserves	$ 5.2
Collaborative Arrangement \| MTPC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement termination, contractual time threshold (in days)	180 days
Revenues		20.0
Potential milestone payment receipts	$ 30.0
Collaborative Arrangement \| MTPC \| Patents \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Patent term (in years)	10 years
Collaborative Arrangement \| AbbVie Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement termination, contractual time threshold (in days)	180 days
Potential milestone payment receipts	$ 366.0
Collaborative Arrangement \| AbbVie Inc. \| Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 16.7	$ 21.2	$ 22.3
Collaborative Arrangement \| AbbVie Inc. \| Patents \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Patent term (in years)	10 years